Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928317 | 0.92 | EGFR (0.51) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9928295 | 0.91 | EGFR (0.52) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9928321 | 0.88 | EGFR (0.48) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9928299 | 0.86 | EGFR (0.48) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9943135 | 0.85 | EGFR (0.51) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9928291 | 0.85 | EGFR (0.53) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9903974 | 0.84 | EGFR (0.64) | EGFRABL1ABL2ERBB2AURKA | |
| SCHEMBL9928301 | 0.83 | EGFR (0.51) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9898479 | 0.80 | EGFR (0.43) | EGFRABL1ABL2ERBB2BRAF | |
| SCHEMBL9943144 | 0.80 | BRAF (0.45) | EGFRERBB2BRAFTNNI3KTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| CN-102482281-A | Pyrrolo [2,3-D ] pyrimidine derivatives | DAIICHI SANKYO CO LTD | 2012-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | EGFR 2/4885ABL1 6/4885ABL2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.